Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study Article

sustainable development goals

SDG 03: Good Health and Well-being

publication date

February 11, 2025

webpage

Web of Science

published in

ADVANCES IN THERAPY Journal

keywords

Adalimumab
Biosimilar
CT-P17
Efficacy
Interchangeability
Pharmacokinetics

start page

1582

end page

1599

volume

42

issue

3